Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 12/20 | 0.39 |
| ▸ | ANPEP | P15144 | 6/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL4864416 | 0.95 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL4138492 | 0.95 | — | — | |
| Cysteine SCHEMBL4872171 | 0.95 | — | — | |
| Cysteine SCHEMBL4864408 | 0.95 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL23903319 | 0.90 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL8501902 | 0.90 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEP | |
| Cysteine SCHEMBL16194528 | 0.90 | — | — | |
| Cysteine SCHEMBL1072972 | 0.90 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL8378977 | 0.90 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Cysteine SCHEMBL5307589 | 0.90 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170191985-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-07-06 | — | — | US | disclosed |
| US-9574223-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140380514-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2014-12-25 | — | — | US | disclosed |
| US-8765969-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8106052-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1546162-B1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110003316-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-7692022-B2 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090023173-A1 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1546162-A4 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1546162-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040171099-A1 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION | 2004-09-02 | — | — | US | disclosed |
| WO-2004027378-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140380514-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | CYP3A43, CYP3A7, CYP3A5 | PTGS1 468/4885SLC7A11 3552/4885ENPEP 889/4885 |
| US-20090023173-A1 | Luminescence-based methods and probes for measuring cytochrome P450 activity | CYP3A43, CYP3A7, CYP3A5 | PTGS1 468/4885SLC7A11 3552/4885ENPEP 889/4885 |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | CYP3A7, CYP3A43, CYP3A5 | PTGS1 578/4885SLC7A11 3103/4885ENPEP 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.